Compare EVR & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVR | EXAS |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 11.0B |
| IPO Year | 2006 | N/A |
| Metric | EVR | EXAS |
|---|---|---|
| Price | $331.74 | $101.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | ★ $320.11 | $76.38 |
| AVG Volume (30 Days) | 344.0K | ★ 10.3M |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | ★ 12.55 | N/A |
| Revenue | ★ $3,542,875,000.00 | $3,082,033,000.00 |
| Revenue This Year | $25.39 | $19.40 |
| Revenue Next Year | $16.43 | $13.51 |
| P/E Ratio | $26.43 | ★ N/A |
| Revenue Growth | ★ 27.03 | 14.47 |
| 52 Week Low | $148.63 | $38.81 |
| 52 Week High | $364.42 | $101.87 |
| Indicator | EVR | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 89.74 |
| Support Level | $310.93 | $100.98 |
| Resistance Level | $322.82 | $101.43 |
| Average True Range (ATR) | 11.11 | 2.25 |
| MACD | 3.21 | 0.53 |
| Stochastic Oscillator | 87.16 | 97.74 |
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.